InfuSystem slides on a Q2 earnings miss

InfuSystem (INFU -3.4%) slips after posting a breakeven Q2, missing Street estimates for a penny profit.

Total revenue rose 4% Y/Y, as rental revenues grew by 5% due to a number of catalysts, including: the addition of larger customers, increased existing account penetration, increased use of its products in colorectal cancer and other cancer patients and the continuation of the revision to claims processing guidelines by a major group of third-party payors.

SG&A decreased to $9.5M from $10.2M, down approximately 8% Y/Y.

Gross margin was 71%, compared to 73% in the prior year. The decrease was primarily related to a decrease in rental gross margins from direct pay customers.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs